מתוך medicontext.co.il
NEW YORK (Reuters Health) – Sildenafil (Viagra; Pfizer, Inc.) administered at its maximum therapeutic dose does not significantly alter intraocular pressure (IOP) in men with well controlled, chronic open-angle glaucoma. According to Dr. Juan E. Grunwald and associates, of the University of Pennsylvania in Philadelphia, this is the first report to specifically investigate the effect of this drug on men with glaucoma.
Fifteen men with a history of elevated IOP, visual field defects, and cup-to-disk ratios consistent with glaucoma were being treated with topical medication. Dr. Grunwald and his associates gave the men a single dose of sildenafil 100 mg or matching placebo on two separate days.
Measurements of IOP at baseline and hourly for 5 hours revealed no clinically or statistically significant variation in IOP for sildenafil compared with placebo, the investigators report in the December issue of the American Journal of Ophthalmology.
To rule out the potential for masked fluctuations in individual patients, the researchers evaluated maximum changes in IOP from baseline. For both sildenafil and placebo, no increases over 6 mm Hg or decreases over 4 mm Hg were observed.
Blood pressures and heart rates were similarly unaffected by sildenafil treatment. "The only potential adverse effect encountered during the study was one instance of hiccups lasting from the second to the third hour after sildenafil administration," Dr. Grunwald's group writes.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!